Drugs chronically blocking the vasopressin type 2 receptor (V2R), such as tolvaptan, may harm people with pulmonary arterial hypertension (PAH) by…
Articles by Magdalena Kegel
Recent advances made, and insights gained, in clinical and preclinical research into pulmonary hypertension were highlighted in a Clinical Year…
A systematic review of clinical trial data showed that exercise training improves exercise capacity and the quality of life…
Chinese researchers identified a number of risk factors for the development of pulmonary hypertension (PH) in patients under maintenance peritoneal dialysis…
A recent Japanese study suggested that it might be more advantageous to combine sildenafil with ambrisentan than with bosentan as…
Prostacyclin analogs have substantially improved pulmonary arterial hypertension (PAH) treatment, but the use of these drugs is hampered by the…
People newly diagnosed with pulmonary arterial hypertension (PAH) are at greater risk of disease progression than PAH patients sick for more than six months,…
A study from the University of Alabama at Birmingham showed that the immune receptor TLR4 is important for regulating the…
A case report from Texas Children’s Hospital described a 5-year-old boy with a newly identified mutation in the BMP9 gene…
Pulmonary arterial hypertension (PAH) is a common condition in infants undergoing surgery for congenital heart defects, and it is a…
Targeting the nitric oxide deficiency resulting from pulmonary arterial hypertension through drugs such as sildenafil is a cornerstone of PAH treatment.
A study reported that certain cells in the lungs act as sensors, linking the pulmonary and central nervous systems to regulate immune responses in reaction…